Free Trial

Organigram (TSE:OGI) Stock Price Down 0.4% - Here's Why

Organigram logo with Medical background

Key Points

  • Organigram Holdings Inc. (TSE:OGI) saw its stock price decrease by 0.4%, trading down to C$2.27 with a significant decline in trading volume, down 81% from its average daily volume.
  • The company has a market capitalization of C$303.92 million and a notably high P/E ratio of 189.17, indicating potentially high valuation concerns.
  • Organigram focuses on producing high-quality, indoor-grown cannabis products for both medical and recreational use.
  • Interested in Organigram? Here are five stocks we like better.

Organigram Holdings Inc. (TSE:OGI - Get Free Report) shares traded down 0.4% during mid-day trading on Monday . The company traded as low as C$2.22 and last traded at C$2.27. 32,706 shares traded hands during trading, a decline of 81% from the average session volume of 171,217 shares. The stock had previously closed at C$2.28.

Organigram Price Performance

The company has a market cap of C$306.59 million, a PE ratio of 190.83, a price-to-earnings-growth ratio of 0.42 and a beta of 2.08. The business's 50 day moving average price is C$2.10 and its 200-day moving average price is C$1.80. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07.

Organigram Company Profile

(Get Free Report)

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Further Reading

Should You Invest $1,000 in Organigram Right Now?

Before you consider Organigram, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.

While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.